Commentary Open Access
Volume 1 | Issue 2 | DOI: https://doi.org/10.33696/haematology.1.010
Needed, Assays for “Fetal Hemoglobin levels” in RBCs: Fetomaternal Hemorrhage and Expanded Applications in Sickle Cell Disease Management Could Forge an Evolution in Cellular Diagnostics
Bruce H. Davis1,*
- 1Department of Microbiology, University of Porto Faculty of Medicine, Porto, Portugal
Corresponding Author
Bruce H. Davis, davis.bruce@gmail.com
Received Date: September 09, 2020
Accepted Date: September 23, 2020
Davis BH. Needed, Assays for “Fetal Hemoglobin levels” in RBCs: Fetomaternal Hemorrhage and Expanded Applications in Sickle Cell Disease Management Could Forge an Evolution in Cellular Diagnostics. J Clin Haematol. 2020; 1(2):66-71.
Copyright: © 2020 Davis BH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Pseudothrombocytosis Due to Red Blood Cell Fragmentation in Haemoglobin-H Disease
Red cell membrane in patients with haemoglobin H (Hb-H) disease and other haemoglobinopathies is rigid and thus red blood cells are fragmented during passage through narrow capillary beds, especially through the splenic sinusoids and the liver [1,2]. These fragments are frequently seen in peripheral blood films.
Gene Therapy for Sickle Cell Disease: Start of a New Era
This manuscript reviews treatment of Sickle Cell disease over time. The application of allogeneic stem cells proved the sickle cell disease could be permanently corrected and cured but limited to those with a compatible donor.
Needed, Assays for “Fetal Hemoglobin levels” in RBCs: Fetomaternal Hemorrhage and Expanded Applications in Sickle Cell Disease Management Could Forge an Evolution in Cellular Diagnostics
Treatment of sickle cell disease (SCD) remains varied with only a minority of patients benefiting from stem cell transplant as a near cure. Others await the promise of more effective and less toxic treatments than hydroxyurea, especially children who are most susceptible to the morbidities and mortalities of SCD. The recent report of Hebert, Rakotoson et al. points to an evolution of in vitro diagnostics (IVD) testing of blood cells with the emerging need for cell-by-cell measurement of red blood cell (RBC) specific hemoglobin variant levels. The study further provides clinical validation as to the utility of measuring HbF content in RBCs of SCD patients, not just as a prognostic test, but likely serving as a companion diagnostic in phase 3 clinical trials of new SCD therapies.
Preventing Stroke in Sickle Cell Disease: 2021. The Role of Transcranial Doppler Ultrasound (TCD) When the Use of Transfusion is Problematic
While TCD is an indicator of risk, not a biopsy diagnosis (such as proof of cancer), at some point in the velocity spectrum the high velocity detected by TCD reaches what many believe is an unacceptable risk of stroke.
Phlebotomy in Congenital Erythrocytosis and in Sickle Cell Disease HbSC
The inherited haemoglobin disorders, including thalassemias and haemoglobinopathies, are the most common genetic diseases and the clinical laboratory is essential in the diagnosis. Haemoglobinopathies are monogenic disorders in the genes that encode globin chains that can lead to a defective globin production or a variant in the haemoglobin structure.